KISSEI PHARMACEUTICAL (4547) FY2027 Q1 Earnings Report

Quick View

Executive Summary

Although the Company secured revenue growth in the quarter, its core earning power declined, while the increase in net income was supported by temporary extraordinary gains. Revenue was ¥23.39B (+5.4% year on year), Operating Income was ¥1.09B (-48.0%), and Ordinary Income was ¥2.19B (-25.0%), all trending lower year on year. Meanwhile, consolidated Net Income increased to ¥4.76B (+5.3%; Net Income attributable to owners of the parent was ¥4.72B, +4.5%), securing an increase in earnings. The primary reason for the decline in Operating Income was that SG&A expenses increased 15.2% year on year, exceeding revenue growth (+5.4%). The increase in Net Income resulted from the recognition of ¥4.11B in extraordinary gains, including a ¥4.09B gain on sales of investment securities, representing a divergence from recurring earning power.

Factors Affecting Performance

【Revenue】Revenue was ¥23.39B, representing a 5.4% year-on-year increase. By segment (based on the segment total and composition ratio), the core Pharmaceuticals Business grew to ¥19.46B (+4.2%, composition ratio 79.1%), while the Information Services Business increased to ¥3.57B (+26.9%, composition ratio 14.5%). In contrast, the Construction and Facility Maintenance Business declined to ¥1.30B (-28.3%, composition ratio 5.3%), and the Merchandise Sales Business decreased to ¥0.27B (-8.1%, composition ratio 1.1%). The primary drivers of revenue growth were the strong growth of the Information Services Business and the resilience of the Pharmaceuticals Business, while the contraction of the two non-core businesses partially restrained overall growth.

【Profit and Loss】Operating Income was ¥1.09B (-48.0%), and the Operating Income margin declined to 4.7% from 9.5% in the previous year, a decrease of 4.8pt. While the cost of sales ratio was largely unchanged, SG&A expenses expanded to ¥10.34B (44.2% of revenue, compared with 40.4% in the previous year), making the increase in expenses greater than revenue growth and serving as the primary cause of the earnings decline. By segment, Operating Income in the Pharmaceuticals Business deteriorated significantly to ¥0.62B (-65.5%, margin 3.2%), weighing on company-wide earnings, while the Information Services Business recorded ¥0.30B (+317.8%, margin 8.6%), showing a notable improvement in profitability. Supported by ¥1.12B in non-operating income, including ¥0.68B in dividend income, Ordinary Income stood at ¥2.19B (-25.0%). However, extraordinary gains of ¥4.11B, primarily consisting of a ¥4.09B gain on sales of investment securities, lifted Profit Before Tax to ¥6.29B, resulting in a 5.3% increase in Net Income to ¥4.76B. In conclusion, the Company achieved higher revenue but lower operating and ordinary profit, while Net Income increased due to temporary factors.

Segment Analysis

The most notable feature is the widening profitability gap among segments. The Pharmaceuticals Business was the largest segment, with revenue of ¥19.46B (+4.2%) and a composition ratio of 79.1%, but Operating Income fell to ¥0.62B (-65.5%), and its margin declined sharply to 3.2% from an estimated approximately 9.7% in the previous year. The Information Services Business recorded revenue of ¥3.57B (+26.9%), Operating Income of ¥0.30B (+317.8%), and a margin of 8.6% (2.6% in the previous year), demonstrating progress toward high growth and improved profitability and supporting the company-wide margin. The Construction and Facility Maintenance Business maintained a 7.6% margin despite revenue of ¥1.296B (-28.3%), while the Merchandise Sales Business recorded revenue of ¥0.27B (-8.1%) and approximately zero Operating Income. The decline in the company-wide Operating Income margin was primarily attributable to deteriorating profitability in the Pharmaceuticals Business, which accounts for approximately 80% of the composition, while growth in the Information Services Business partially offset the impact.

Key Financial Metrics

【Profitability】The Operating Income margin was 4.7%, down 4.8pt from 9.5% in the previous year, while the gross margin also declined slightly to 48.9% from 49.9%. 【Cash Quality】Comprehensive Income was ¥3.06B, ¥1.70B below consolidated Net Income of ¥4.76B. This was attributable to fluctuations in other securities valuation, including a -¥1.49B valuation difference on securities and a -¥0.22B adjustment related to retirement benefits. 【Investment Efficiency】ROE was 2.1%. Investment securities accounted for ¥104.58B of total assets of ¥270.24B (38.7% of total assets), and the balance sheet’s heavy weighting toward financial assets has contributed to a persistently low asset turnover ratio. 【Financial Soundness】The Equity Ratio remained high at 85.3% (83.7% in the previous year), while the current ratio was 602.6%. With interest-bearing debt of ¥1.25B versus cash and deposits of ¥30.64B, the Company was in a net cash position, and its interest coverage ratio was 136.9 times, indicating extremely strong debt-servicing capacity.

Cash Flow Analysis

As cash flow statement data are unavailable, cash trends are analyzed based on changes in the balance sheet. Cash and deposits increased to ¥30.64B (¥29.06B in the previous year, +5.4%), indicating an expansion in liquidity on hand. Current liabilities declined to ¥18.29B (¥21.69B in the previous year, -15.7%), primarily because income taxes payable decreased significantly to ¥1.28B (¥5.01B in the previous year, -74.5%) and the provision for bonuses declined to ¥0.88B (¥2.30B in the previous year, -61.7%). Meanwhile, contract liabilities (advance payments) increased to ¥1.62B (¥0.85B in the previous year, +90.9%), indicating an accumulation of advance payments for future service provision. Current securities declined to ¥22.32B (¥25.37B in the previous year, -12.0%), suggesting that a partial review of the asset composition, including sales of investment securities, may have progressed. Overall, debt reduction and the accumulation of cash on hand progressed in parallel, expanding financial flexibility from the previous year.

Quality of Earnings

When recurring earnings and temporary items are distinguished, the results indicate a high degree of dependence on non-recurring items. Against Operating Income of ¥1.09B, the Company recorded ¥1.12B in non-operating income (4.8% of revenue, primarily ¥0.68B in dividend income) and ¥4.11B in extraordinary gains (including a ¥4.09B gain on sales of investment securities). Consequently, Ordinary Income accounted for only ¥2.19B of Profit Before Tax of ¥6.29B. The effective tax rate was 24.3%, calculated as ¥1.53B in income taxes and other taxes divided by Profit Before Tax of ¥6.29B, broadly in line with the previous year. Comprehensive Income was ¥3.06B, below consolidated Net Income of ¥4.76B, with fluctuations in the fair value of securities creating a divergence from Net Income. The increase in Net Income was highly dependent on the temporary factor of gains on sales of investment securities, and evaluation should focus on the trend in core Operating Income.

Earnings Forecast and Guidance

Progress against the full-year forecast was substantially ahead of the standard quarterly progress rate of 25% for Operating Income and Ordinary Income. Revenue reached 26.4% progress against the full-year forecast of ¥88.70B (the full year is expected to decline 8.9% year on year), Operating Income reached 54.8% against ¥2.00B, Ordinary Income reached 54.6% against ¥4.00B, and Net Income attributable to owners of the parent reached 35.5% against ¥13.30B. The high progress rates for Operating Income and Ordinary Income were largely attributable to the recognition of extraordinary gains, including gains on sales of investment securities. It should therefore be noted that progress on a core Operating Income basis was more moderate. The earnings forecast was revised during the quarter, and the recovery of profitability in the core businesses will be the key issue for achieving the full-year plan.

Shareholder Returns

The full-year dividend forecast is ¥170 per share, including a ¥40 commemorative dividend marking the 80th anniversary of the Company’s founding. The Payout Ratio against forecast EPS of ¥326.97 is 52.0%, calculated as ¥170 ÷ ¥326.97, a level within a generally sustainable range. There was no revision to the dividend forecast during the quarter; only the earnings forecast was revised. Given the Company’s minimal interest-bearing debt and net cash position, its financial foundation for dividend funding is reasonably strong.

Risk Factors

1. Deteriorating profitability in the core Pharmaceuticals Business: The Operating Income margin of the Pharmaceuticals Business was 3.2%, down sharply from an estimated approximately 9.7% in the previous year, while Operating Income was ¥0.62B (-65.5%). As the core business accounts for approximately 79% of the revenue composition, its declining profitability has a significant impact on company-wide earnings.

2. Earnings structure dependent on extraordinary gains: Extraordinary gains accounted for ¥4.11B of Profit Before Tax of ¥6.29B, including a ¥4.09B gain on sales of investment securities, representing a substantial divergence from the recurring earnings level reflected in Ordinary Income of ¥2.19B. This gain was a temporary factor, and if gains of a similar magnitude are not recorded in subsequent periods, earnings could decline sharply on a reversal effect.

3. Contraction of non-core segments: The Construction and Facility Maintenance Business recorded a 28.3% decline in revenue, while the Merchandise Sales Business also recorded an 8.1% decline, indicating that the contraction trend in the two non-core segments is continuing.

Industry Benchmark (For Reference; Compiled by the Company)

Profitability and Return

The Operating Income margin was substantially below the industry median, while the Net Income margin exceeded the industry median due to the recognition of extraordinary gains.

Growth and Capital Efficiency

The revenue growth rate was below the industry median, placing the Company somewhat behind its industry peers in terms of growth.

※Source: Compiled by the Company

Key Takeaways from the Financial Results

1. The Operating Income margin fell sharply to 4.7% from 9.5% in the previous year, indicating that the increase in expenses pressured profitability, as SG&A expense growth (+15.2%) exceeded revenue growth (+5.4%).

2. The increase in consolidated Net Income (+5.3%) was largely attributable to extraordinary gains, including a ¥4.09B gain on sales of investment securities. Given that Ordinary Income declined 25.0%, earnings quality remains highly dependent on temporary factors.

3. By segment, the Information Services Business achieved high growth and improved profitability, with revenue up 26.9% and Operating Income up 317.8%. Meanwhile, the core Pharmaceuticals Business recorded higher revenue but a 65.5% decline in Operating Income, indicating divergent performance across the business portfolio.

Theoretical Share Price (Reference Value)

This is a reference range mechanically calculated solely from publicly available data using a residual income model (Ohlson-type model with an explicit 5-year fade period). It is not a forecast of the market share price or a recommendation of any specific investment action.

Sensitivity: ¥4,208–¥4,448 at ±1% for the cost of equity, and ¥4,288–¥4,350 at ±0.1 for ω.

Notes:

• Normalized EPS calculated from Ordinary Income and other metrics is used to exclude the impact of temporary profit and loss items (the Company’s forecast EPS is ¥327.0).
• Because progress of Net Income against the full-year forecast (36%) exceeds the standard rate (25%), forecast EPS is adjusted upward within a maximum range of +10% (because companies ahead of schedule tend to exceed forecasts; the adjustment may be excessive for businesses with strong seasonality).
• Because forecast ROE is below the cost of equity, the theoretical value is below book value per share.
• Net assets as of the end of the quarter are used (there is a timing difference from the full-year forecast).

(Model used: Residual Income Model / Interest Rate Reference Month: 2026-06 / This value does not predict or guarantee future share prices)

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings release data. It does not recommend investment in any specific security. Industry benchmarks are reference information compiled by the Company based on publicly available earnings data. Investment decisions should be made at your own responsibility, and after consulting a professional adviser as necessary.

---End of Report---

---

AI Financial Analysis

Executive Summary

FY2027 Q1 results were characterized by modest top-line growth but a sharp deterioration in underlying operating profitability, while reported net income was supported by a large securities-sale gain. Revenue increased 5.4% year on year to ¥23.39bn. Gross profit rose to ¥11.43bn, but the gross margin declined 105bp to 48.9%. SG&A expense increased 15.2% to ¥10.34bn, substantially outpacing revenue growth. Consequently, operating income fell 48.0% to ¥1.10bn. The operating margin compressed 482bp from 9.5% to 4.7%, falling below the 5% low-efficiency threshold. Ordinary income declined 25.0% to ¥2.19bn, with dividend income of ¥0.68bn remaining an important contributor to earnings outside operations. Net income attributable to owners nevertheless rose 4.5% to ¥4.72bn. This apparent resilience was driven principally by a ¥4.09bn gain on sales of investment securities, compared with ¥2.86bn in the prior-year quarter. The securities gain represented 17.5% of quarterly revenue and means reported net margin of 20.2% does not represent recurring operating profitability. Comprehensive income declined 46.2% to ¥3.06bn as securities valuation losses and defined-benefit remeasurement losses offset reported profit. The balance sheet remains exceptionally liquid, with a 602.6% current ratio, ¥30.64bn of cash and deposits, and only ¥1.25bn of interest-bearing debt. Investment securities of ¥104.58bn, equal to 38.7% of assets, are a defining feature of both the capital structure and earnings profile. Pharmaceutical segment profit fell materially despite revenue growth, indicating that cost pressure or spending intensity is concentrated in the core business. Management's full-year operating-income forecast of ¥2.00bn implies Q1 progress of 54.8%, well above the standard 25% first-quarter pace, but this should not be read as evidence of sustainably strong operations because Q1 operating income itself declined sharply year on year. Full-year sales guidance of ¥88.70bn implies a 26.4% Q1 progress rate, broadly consistent with normal seasonality, while the forecast indicates a 8.9% year-on-year revenue decline. The key forward issue is whether the company can restore pharmaceutical segment margins and deliver its forecast without continued reliance on investment-security realizations.

Profitability Analysis

Annualized DuPont ROE is 8.2%, comprising a 20.2% net profit margin, 0.346x asset turnover, and 1.17x financial leverage. The low leverage factor confirms that shareholder returns are not being created through balance-sheet gearing; the company is conservatively capitalized. However, the reported net margin is substantially flattered by the ¥4.09bn extraordinary gain on securities sales. The most consequential underlying change was the operating margin's 482bp contraction to 4.7%, as SG&A rose 15.2% against 5.4% revenue growth. Gross margin also declined 105bp to 48.9%, indicating that the profit shortfall was not solely a fixed-cost absorption issue. In the extended DuPont framework, the 0.751 tax burden is normal and the 5.747 interest-burden ratio reflects substantial non-operating and extraordinary income relative to EBIT rather than debt-financing pressure. Interest coverage remains very strong at 136.9x. Core pharmaceutical segment profit declined 65.5% to ¥6.24bn despite 4.2% external revenue growth to ¥19.46bn, causing its segment margin on external sales to fall from 9.7% to 3.2%. Information services was the main positive offset: external revenue increased 34.8% to ¥3.07bn and segment profit rose to ¥3.05bn from ¥0.73bn. Construction and facilities maintenance external revenue declined 38.8% to ¥0.61bn, while segment profit fell 24.6% to ¥0.98bn. Merchandise sales remained small and its segment result was approximately break-even. The quality alert for low operating efficiency is warranted: the 4.7% EBIT margin is below both the 5% warning threshold and the level typically expected from a branded pharmaceutical business. The capital-efficiency alert is also material, as reported ROIC of 1.6% is below 5%, reflecting a large investment-asset base and weak operating profit generation. Improvement in ROE and ROIC would require a recovery in recurring operating margin and more productive deployment of the substantial securities portfolio, rather than further one-off asset sales.

Growth Assessment

Revenue growth was positive in Q1, led by domestic pharmaceutical sales, which increased 4.6% to ¥17.12bn, and information services revenue, which increased 26.9% to ¥3.57bn including internal sales. Export and overseas licensing revenue grew 3.6% to ¥1.48bn, while healthcare food sales declined 2.6% to ¥0.86bn. The mix of growth is therefore favorable at the revenue level, but not yet translating into core pharmaceutical profit expansion. Pharmaceutical segment profit deterioration despite sales growth points to unfavorable cost of sales, promotional expense, R&D-related spending, product mix, or other operating-cost pressure; the provided figures do not isolate these factors. The FY2027 sales forecast is ¥88.70bn, implying a 8.9% year-on-year decline for the full year and making Q1 growth potentially difficult to extrapolate. Q1 sales represent 26.4% of the full-year forecast, close to the standard 25% first-quarter pace. Q1 operating income of ¥1.10bn represents 54.8% of the ¥2.00bn full-year forecast, and ordinary income of ¥2.19bn represents 54.6% of the ¥4.00bn forecast, both more than 10 percentage points above a standard Q1 progress rate. Net income attributable to owners of ¥4.72bn is 35.5% of the ¥13.30bn full-year forecast, also ahead of the standard pace. The above-normal earnings progress is principally associated with the realized securities gain, so the full-year earnings path depends on the timing and recurrence of investment gains as well as operating-margin recovery. For a pharmaceutical issuer, sustaining growth ultimately depends on product lifecycle management, new-product uptake, pricing conditions, and development productivity; current-period quantitative disclosures do not permit an assessment of pipeline advancement or R&D intensity.

Financial Health

Financial health is strong. Current assets of ¥110.22bn exceed current liabilities of ¥18.29bn by ¥91.93bn, producing a 602.6% current ratio and a 532.8% quick ratio. Cash and deposits of ¥30.64bn alone cover short-term loans of ¥1.25bn by 24.51x. Interest-bearing debt is limited to ¥1.25bn, equivalent to 0.5% of capital under the reported debt/capital metric, and the reported debt-to-equity ratio is 0.17x. Total liabilities account for only 14.7% of total assets, while the capital adequacy ratio is 84.8%. Interest expense was only ¥0.08bn and is comfortably supported by EBIT. The 100% short-term debt ratio triggers the refinancing-risk alert because all identified debt matures within one year rather than being term-funded. In practical terms, the risk is low at present because cash resources are more than sufficient to repay the debt, but the maturity concentration should still be monitored if borrowing increases. The company also has ¥104.58bn of investment securities and ¥22.32bn of short-term investment securities, providing considerable financial flexibility but exposing equity and comprehensive income to market-value movements. Deferred tax liabilities of ¥20.70bn are substantial relative to total liabilities and are consistent with the large securities-related balance-sheet exposure. No leverage-based warning is indicated: neither the current ratio nor debt-to-equity ratio approaches the specified risk thresholds.

Notable B/S Changes

Accounts payable: -¥1.41bn (-21.2% YoY) to ¥5.25bn - lower supplier balances may reduce financing support within the cash conversion cycle. Provision for bonuses: -¥1.42bn (-61.7% YoY) to ¥0.88bn - a substantial reduction in accrued personnel-related obligations contributed to lower current liabilities. Contract liabilities: +¥0.77bn (+90.9% YoY) to ¥1.62bn - increased customer advances/deferred revenue may support near-term revenue visibility or reflect contract-timing changes.

Cash Flow Quality

Reported profit quality is weak on a recurring-earnings basis because net income of ¥4.72bn exceeded operating income of ¥1.10bn by more than four times, primarily due to the ¥4.09bn gain on sales of investment securities. The gain is cash-generating when settled, but it is not a substitute for recurring cash generation from pharmaceutical operations. Cash and deposits increased ¥1.58bn year on year to ¥30.64bn, while short-term investment securities declined ¥3.05bn to ¥22.32bn, indicating substantial liquid financial resources. Working-capital efficiency requires attention. The quality alerts identify annualized DSO of 108 days, above the 60-day threshold, which implies comparatively slow conversion of receivables into cash. They also identify inventory days of 197 days and 98 days under separate measures, each above their respective thresholds; regardless of methodology, inventory conversion is extended. The associated cash conversion cycle alert of 265 days, above 120 days, reinforces that operating capital is tied up for a long period. Finished-goods inventory increased 2.5% year on year to ¥12.78bn, while accounts receivable declined 12.0% to ¥27.80bn and trade payables declined 21.2% to ¥5.25bn. The reduction in payables may reduce supplier-financing support for the cash conversion cycle, although the balance-sheet liquidity buffer remains ample. These working-capital indicators are particularly relevant for a pharmaceutical manufacturer because demand forecasting, inventory expiry, reimbursement timing, and supply-chain management can affect both cash conversion and inventory-obsolescence risk. Operating cash flow, investing cash flow, capital expenditure, free cash flow, and OCF-to-net-income conversion are not quantified in the supplied period data; therefore, coverage of dividends and investment commitments by internally generated free cash flow cannot be assessed.

Dividend Sustainability

The FY2027 full-year dividend forecast is ¥170 per share against forecast EPS of ¥326.97, implying a dividends-only payout ratio of approximately 52.0%. This is below the 60% sustainability benchmark and appears supportable from forecast accounting earnings. The forecast includes a ¥40 per-share 80th-anniversary commemorative dividend in the planned FY2027 interim dividend, indicating that the stated annual payout includes a non-recurring shareholder-return component. On an earnings basis, the dividend policy therefore appears conservatively funded, aided by the company's low debt and large liquidity and securities holdings. Q1 EPS was ¥113.95, equal to 34.9% of forecast full-year EPS, although this quarterly result includes the large securities-sale gain. Recurring dividend capacity should consequently be assessed primarily against future operating and ordinary earnings rather than Q1 reported net income. No share-buyback amount is provided, so a total return ratio cannot be calculated. Free-cash-flow coverage cannot be quantified from the available data. The principal sustainability risk is not balance-sheet solvency but a prolonged period of sub-5% operating margin and reliance on realized investment gains to support earnings.

Risk Assessment

Business risks include Core pharmaceutical profitability risk: pharmaceutical segment profit fell 65.5% year on year to ¥6.24bn despite 4.2% growth in external segment revenue, reducing the segment margin to 3.2% from 9.7%., Pharmaceutical industry risk: drug pricing reforms, generic competition, product lifecycle pressure, regulatory requirements, and clinical-development outcomes could constrain sales growth and margins., Working-capital risk: the quality alerts show annualized DSO of 108 days, inventory days of 197 days and 98 days under separate measures, and a 265-day cash conversion cycle; this increases exposure to collection timing, demand forecasting, expiry, and inventory-obsolescence risk., Information-services growth is positive but may not fully offset a sustained deterioration in the much larger pharmaceutical business., Construction and facilities maintenance external sales declined 38.8%, highlighting volatility outside the core pharmaceutical operation..

Financial risks include Earnings concentration in non-recurring securities sales: the ¥4.09bn gain on sale of investment securities was 17.5% of revenue and was the major source of the gap between EBIT and profit before tax., Market-value risk is material because investment securities total ¥104.58bn, or 38.7% of total assets; securities valuation losses contributed to the 46.2% decline in comprehensive income., All identified interest-bearing debt is short term, resulting in a 100% short-term debt ratio and the refinancing-risk alert, although the ¥30.64bn cash balance provides substantial repayment capacity., Low capital efficiency: reported ROIC of 1.6% is below the 5% threshold and annualized ROE of 8.2% is only modestly above the stated concern threshold..

Key concerns include SG&A rose 15.2% while revenue grew only 5.4%, driving a 482bp operating-margin contraction to 4.7%., Full-year operating-income progress is 54.8% in Q1, but the absolute Q1 operating-income result was down 48.0% year on year; the apparent forecast cushion should be evaluated cautiously., The ¥4.09bn securities-sale gain boosted net income but does not resolve the underlying operating-profit decline., Inventory and receivables efficiency warrant monitoring even though headline liquidity is exceptionally strong..

Investment Implications

Key takeaways include Revenue growth was 5.4%, but underlying operating income declined 48.0% and operating margin compressed to 4.7%., The pharmaceutical segment remains the core business by revenue contribution, but its segment profit fell 65.5%, making margin recovery the central operating issue., Reported net income growth of 4.5% was driven by a ¥4.09bn gain on sale of investment securities rather than by recurring operating improvement., The balance sheet provides substantial resilience through low debt, high liquidity, and a large securities portfolio., FY2027 dividend guidance implies a 52.0% payout ratio based on forecast EPS, although the announced amount includes a commemorative dividend component..

Metrics to watch include Pharmaceutical segment revenue growth and segment margin recovery from 3.2%, Operating margin relative to the current 4.7% level, SG&A growth relative to sales growth, Recurring ordinary income excluding dividends and gains on securities sales, DSO, inventory days, and cash conversion cycle, Investment-security realizations and securities valuation movements in other comprehensive income, Progress versus the ¥88.70bn sales, ¥2.00bn operating-income, ¥4.00bn ordinary-income, and ¥13.30bn net-income forecasts.

Regarding relative positioning, The company is positioned as financially defensive rather than operationally efficient: its capital structure, liquidity, and interest coverage are materially stronger than typical leverage-sensitive peers, but its current 4.7% operating margin and 1.6% reported ROIC are weak for a pharmaceutical company. Its large securities portfolio supplies financial flexibility and dividend support, but also makes reported earnings and comprehensive income more sensitive to asset realizations and market valuations.